Haemonetics Corp.

HAE

$88.16

+22.3% last 12 months

Chuck Royce Holding value: $79.9 Million Ken Fisher Holding value: $79.6 Million Jim Simons Holding value: $6.29 Million Ray Dalio Holding value: $4.87 Million Joel Greenblatt Holding value: $1.87 Million Ken Griffin Holding value: $149 Thousand Third Avenue Management Holding value: $0 First Eagle Investments Holding value: $0 Steven Cohen Holding value: $0 George Soros Holding value: $0

Market Cap

$4.62 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$72.26 - $95.26

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

33.85x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $4.62 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $5.1 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. +22.3%
52-Week High Highest share price in the last 52 weeks. $95.26
52-Week Low Lowest share price in the last 52 weeks. $72.26
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.73
Outstanding Shares The number of shares the company has issued and are held by stockholders. 50.7 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 288 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 33.85
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 31.79
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $2.66
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 3.67
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 5.19
Enterprise Value to Revenue Enterprise value divided by revenue 4.19
Enterprise Value to EBIT Enterprise Value divided by EBIT 28.58
Total Debt to Enterprise Value Total debt divided by enterprise value 0.15
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.88

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $1.22 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $640 Million
EBIT Earnings before tax and interest payments. $179 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $137 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 11.21%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +106.5%
Return on Equity Equity divided by market cap. 15.79%
Return on Assets Indicates a company's profitability in relation to its total assets. 6.96%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 10.35%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2023 Q2 2023 Q3 2023 Q4 2023

About Haemonetics Corp.

CEO: Christopher Simon

Industry: Surgical and Medical Instrument Manufacturing

Similar stocks

Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Stryker Corp.
Stryker Corp.
Becton Dickinson & Co.
Becton Dickinson & Co.
Cerus Corp.
Cerus Corp.
Baxter International Inc.
Baxter International Inc.
Revvity Inc.
Revvity Inc.
Johnson & Johnson
Johnson & Johnson
Medtronic Plc
Medtronic Plc

News

Citi opens upside catalyst watch for Haemonetics ahead of earnings report

Citi opens upside catalyst watch for Haemonetics ahead of earnings report

Citi has opened an upside catalyst watch for Haemonetics ahead of the medtech''s FYQ2 2024 earnings report and expects management to raise guidance. Read mor...

Seeking Alpha Seeking Alpha, 1 day ago
Martingale Asset Management L P Grows Stock Holdings in Haemonetics Co. (NYSE:HAE)

Martingale Asset Management L P Grows Stock Holdings in Haemonetics Co. (NYSE:HAE)

Martingale Asset Management L P boosted its holdings in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 3.8% during the first quarter, Holdings Channel...

The AM Reporter The AM Reporter, about 1 month ago
Haemonetics Receives Strong-Buy Rating and Shows Potential for Long-Term Gains

Haemonetics Receives Strong-Buy Rating and Shows Potential for Long-Term Gains

In an exciting development for investors, Haemonetics (NYSE:HAE) received an upgrade by StockNews.com from a “buy” rating to a “strong-buy” rating on August ...

Best Stocks Best Stocks, about 1 month ago
Zacks Research Equities Analysts Decrease Earnings Estimates for Haemonetics Co. (NYSE:HAE)

Zacks Research Equities Analysts Decrease Earnings Estimates for Haemonetics Co. (NYSE:HAE)

Haemonetics Co. (NYSE:HAE – Free Report) – Equities research analysts at Zacks Research reduced their Q4 2024 earnings per share (EPS) estimates for shares o...

The AM Reporter The AM Reporter, about 1 month ago
Never miss a trade
To improve your user experience we use cookies.